Literature DB >> 11019934

Anxiety disorders: a review of tricyclic antidepressants and selective serotonin reuptake inhibitors.

J Zohar1, H G Westenberg.   

Abstract

OBJECTIVE: Anxiety disorders are the most common mental health disorders. While the older tricylic antidepressants (TCAs) are efficacious in the treatment of many anxiety disorders, recent studies with fluoxetine and other selective serotonin reuptake inhibitors (SSRIs) have emphasized the role of serotonin in the aetiology of these conditions.
METHOD: We reviewed the efficacy, safety and tolerability of TCAs and SSRIs in the treatment of the most common anxiety disorders, specifically, panic disorder, obsessive-compulsive disorder, post-traumatic stress disorder, social phobia and generalized anxiety disorder.
RESULTS: Both the TCA and SSRI antidepressants are effective in treating a wide variety of anxiety disorders. SSRIs, due to their greater safety and tolerability, should be the preferred choices in treating anxiety disorders in those instances where TCAs and SSRIs are considered equally effective. In the cases of OCD and social phobia, SSRIs are almost always preferable given that the TCAs do not appear effective in these disorders.
CONCLUSION: Further research is needed on the naturalistic long-term use of the TCAs and SSRIs in the treatment of anxiety disorders.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11019934     DOI: 10.1111/j.1600-0447.2000.tb10947.x

Source DB:  PubMed          Journal:  Acta Psychiatr Scand Suppl        ISSN: 0065-1591


  32 in total

Review 1.  Role of pharmacogenomics in individualising treatment with SSRIs.

Authors:  Dalu Mancama; Robert W Kerwin
Journal:  CNS Drugs       Date:  2003       Impact factor: 5.749

2.  The serotonergic projection from the median raphe nucleus to the ventral hippocampus is involved in the retrieval of fear memory through the corticotropin-releasing factor type 2 receptor.

Authors:  Yu Ohmura; Takeshi Izumi; Taku Yamaguchi; Iku Tsutsui-Kimura; Takayuki Yoshida; Mitsuhiro Yoshioka
Journal:  Neuropsychopharmacology       Date:  2010-01-13       Impact factor: 7.853

3.  Studies of the biogenic amine transporters. 12. Identification of novel partial inhibitors of amphetamine-induced dopamine release.

Authors:  Joseph J Pariser; John S Partilla; Christina M Dersch; Subramaniam Ananthan; Richard B Rothman
Journal:  J Pharmacol Exp Ther       Date:  2008-04-25       Impact factor: 4.030

Review 4.  Anxiety in primary care.

Authors:  Kristen Hope Demertzis; Michelle G Craske
Journal:  Curr Psychiatry Rep       Date:  2006-08       Impact factor: 5.285

5.  Serotonin depletion eliminates sex differences with respect to context-conditioned immobility in rat.

Authors:  Robert Pettersson; Sven Melker Hagsäter; Elias Eriksson
Journal:  Psychopharmacology (Berl)       Date:  2016-02-24       Impact factor: 4.530

6.  Depression treatment patterns among adults with chronic obstructive pulmonary disease and depression.

Authors:  Arijita Deb; Usha Sambamoorthi
Journal:  Curr Med Res Opin       Date:  2016-11-11       Impact factor: 2.580

7.  5-HT1A receptor blockade reverses GABA(A) receptor alpha3 subunit-mediated anxiolytic effects on stress-induced hyperthermia.

Authors:  Christiaan H Vinkers; Ruud van Oorschot; S Mechiel Korte; Berend Olivier; Lucianne Groenink
Journal:  Psychopharmacology (Berl)       Date:  2010-06-10       Impact factor: 4.530

Review 8.  Treating comorbid anxiety and depression: Psychosocial and pharmacological approaches.

Authors:  Jeremy D Coplan; Cindy J Aaronson; Venkatesh Panthangi; Younsuk Kim
Journal:  World J Psychiatry       Date:  2015-12-22

Review 9.  Anxiety disorders in pregnancy.

Authors:  Bavanisha Vythilingum
Journal:  Curr Psychiatry Rep       Date:  2008-08       Impact factor: 5.285

10.  Reflechi twòp--thinking too much: description of a cultural syndrome in Haiti's Central Plateau.

Authors:  Bonnie N Kaiser; Kristen E McLean; Brandon A Kohrt; Ashley K Hagaman; Bradley H Wagenaar; Nayla M Khoury; Hunter M Keys
Journal:  Cult Med Psychiatry       Date:  2014-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.